Advertisement

Management of metastatic bone disease (MBD)

Published:September 27, 2022DOI:https://doi.org/10.1016/j.injury.2022.09.054
      The commonest malignant condition to present to the orthopaedic surgeon is metastatic bone disease and many malignant pathological fractures are managed in orthopaedic trauma units [
      • Rai P
      • Aziz S
      • Kannan S
      • Ashford R
      • Mitchell L
      • Brown A
      • et al.
      Current surgical management of metastatic pathological fractures of the femur: A multicentre snapshot audit.
      ]. The skeleton is both the most common site of metastasis and the site that produces the greatest morbidity for patients [
      • Stevenson JD
      • McNair M
      • Cribb GL
      • Cool WP.
      Prognostic factors for patients with skeletal metastases from carcinoma of the breast.
      ,
      • Coleman RE
      • Guise TA
      • Lipton A
      • Roodman GD
      • Berenson JR
      • Body JJ
      • et al.
      Advancing treatment for metastatic bone cancer: Consensus recommendations from the second cambridge conference.
      ]. Published in 2022, the British Orthopaedic Association's Standards for Trauma (BOAST) focussing on Metastatic Bone Disease (MBD), produced in conjunction with the British Orthopaedic Oncology Society (BOOS), provides a comprehensive set of auditable recommendations for the early management of such patients [

      BOAST - Management of Metastatic Bone Disease n.d. https://www.boa.ac.uk/resources/boast-management-of-metastatic-bone-disease.html (accessed August 19, 2022).

      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Injury
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rai P
        • Aziz S
        • Kannan S
        • Ashford R
        • Mitchell L
        • Brown A
        • et al.
        Current surgical management of metastatic pathological fractures of the femur: A multicentre snapshot audit.
        Eur J Surg Oncol. 2020; 46: 1491-1495https://doi.org/10.1016/J.EJSO.2020.02.026
        • Stevenson JD
        • McNair M
        • Cribb GL
        • Cool WP.
        Prognostic factors for patients with skeletal metastases from carcinoma of the breast.
        Bone Jt J. 2016; 98Bhttps://doi.org/10.1302/0301-620X.98B2.36185
        • Coleman RE
        • Guise TA
        • Lipton A
        • Roodman GD
        • Berenson JR
        • Body JJ
        • et al.
        Advancing treatment for metastatic bone cancer: Consensus recommendations from the second cambridge conference.
        Clin Cancer Res. 2008; 14: 6387-6395https://doi.org/10.1158/1078-0432.CCR-08-1572
      1. BOAST - Management of Metastatic Bone Disease n.d. https://www.boa.ac.uk/resources/boast-management-of-metastatic-bone-disease.html (accessed August 19, 2022).

        • DiCaprio MR
        • Murtaza H
        • Palmer B
        • Evangelist M.
        Narrative review of the epidemiology, economic burden, and societal impact of metastatic bone disease.
        Ann Jt. 2022; 7 (28–28)https://doi.org/10.21037/AOJ-20-97
        • Maddams J
        • Utley M
        • Møller H.
        Projections of cancer prevalence in the United Kingdom, 2010–2040.
        Br J Cancer. 2012; 107: 1195-1202https://doi.org/10.1038/bjc.2012.366
      2. Schulman KL, Kohles J. Economic Burden of Metastatic Bone Disease in the U.S n.d. doi:10.1002/cncr.22678.

        • Ardakani AHG
        • Faimali M
        • Nystrom L
        • Mesko N
        • Mughal M
        • Ware H
        • et al.
        Metastatic bone disease: Early referral for multidisciplinary care.
        Cleve Clin J Med. 2022; 89 (393 LP –399)https://doi.org/10.3949/ccjm.89a.21062
        • Abbott A
        • Kendal JK
        • Hewison C
        • Puloski S
        • Monument M.
        Longitudinal survival trends of patients with cancer with surgically managed appendicular metastatic bone disease: Systematic review.
        Can J Surg. 2021; 64: E550-E560https://doi.org/10.1503/CJS.015520
        • Adams SC
        • Potter BK
        • Mahmood Z
        • Pitcher JD
        • Temple HT.
        Consequences and Prevention of Inadvertent Internal Fixation of Primary Osseous Sarcomas.
        Clin Orthop Relat Res. 2009; 467: 519https://doi.org/10.1007/S11999-008-0546-3
        • Forsberg JA
        • Wedin R
        • Bauer H.
        Which implant is best after failed treatment for pathologic femur fractures?.
        Tumor Clin Orthop Relat Res. 2013; 471: 735-740https://doi.org/10.1007/s11999-012-2558-2
        • Archer JE
        • Chauhan GS
        • Osman K
        • Thomson C
        • Dewan V
        • Nandra R
        • et al.
        The British Orthopaedic Oncology Management audit protocol.
        J Surg Protoc Res Methodol. 2021; 2021https://doi.org/10.1093/JSPRM/SNAB005
      3. Tillman RM, Ashford RU. Metastatic Bone Disease: A Guide to Good Practice. 2013 Revision CO-CHAIRMEN BOA/BOOS WORKING PARTY n.d.